Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tony Hulse is active.

Publication


Featured researches published by Tony Hulse.


The Journal of Clinical Endocrinology and Metabolism | 2013

Variations in PROKR2, But Not PROK2, Are Associated With Hypopituitarism and Septo-optic Dysplasia

Mark J. McCabe; Carles Gaston-Massuet; Louise Gregory; Kyriaki S. Alatzoglou; Vaitsa Tziaferi; Oualid Sbai; Philippe Rondard; Koh-hei Masumoto; Mamoru Nagano; Yasufumi Shigeyoshi; Marija Pfeifer; Tony Hulse; Charles Buchanan; Nelly Pitteloud; Juan Pedro Martinez-Barbera; Mehul T. Dattani

Context: Loss-of-function mutations in PROK2 and PROKR2 have been implicated in Kallmann syndrome (KS), characterized by hypogonadotropic hypogonadism and anosmia. Recent data suggest overlapping phenotypes/genotypes between KS and congenital hypopituitarism (CH), including septo-optic dysplasia (SOD). Objective: We screened a cohort of patients with complex forms of CH (n = 422) for mutations in PROK2 and PROKR2. Results: We detected 5 PROKR2 variants in 11 patients with SOD/CH: novel p.G371R and previously reported p.A51T, p.R85L, p.L173R, and p.R268C—the latter 3 being known functionally deleterious variants. Surprisingly, 1 patient with SOD was heterozygous for the p.L173R variant, whereas his phenotypically unaffected mother was homozygous for the variant. We sought to clarify the role of PROKR2 in hypothalamopituitary development through analysis of Prokr2−/− mice. Interestingly, these revealed predominantly normal hypothalamopituitary development and terminal cell differentiation, with the exception of reduced LH; this was inconsistent with patient phenotypes and more analogous to the healthy mother, although she did not have KS, unlike the Prokr2−/− mice. Conclusions: The role of PROKR2 in the etiology of CH, SOD, and KS is uncertain, as demonstrated by no clear phenotype-genotype correlation; loss-of-function variants in heterozygosity or homozygosity can be associated with these disorders. However, we report a phenotypically normal parent, homozygous for p.L173R. Our data suggest that the variants identified herein are unlikely to be implicated in isolation in these disorders; other genetic or environmental modifiers may also impact on the etiology. Given the phenotypic variability, genetic counseling may presently be inappropriate.


Human Molecular Genetics | 2015

Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype–phenotype correlations, codon bias and dominant-negative effects

Fadil M. Hannan; Sarah Howles; Angela Rogers; Treena Cranston; Caroline M. Gorvin; Valerie N. Babinsky; Anita Reed; Clare E Thakker; Detlef Bockenhauer; Rosalind S. Brown; John M. Connell; J. Cook; Ken Darzy; Sarah Ehtisham; Una Graham; Tony Hulse; Steven J. Hunter; Louise Izatt; Dhavendra Kumar; Malachi J. McKenna; John McKnight; Patrick J. Morrison; M. Zulf Mughal; Domhnall O'Halloran; Simon Pearce; Mary Porteous; Mushtaqur Rahman; Tristan Richardson; Robert Robinson; Isabelle Scheers

The adaptor protein-2 sigma subunit (AP2σ2) is pivotal for clathrin-mediated endocytosis of plasma membrane constituents such as the calcium-sensing receptor (CaSR). Mutations of the AP2σ2 Arg15 residue result in familial hypocalciuric hypercalcaemia type 3 (FHH3), a disorder of extracellular calcium (Ca2+o) homeostasis. To elucidate the role of AP2σ2 in Ca2+o regulation, we investigated 65 FHH probands, without other FHH-associated mutations, for AP2σ2 mutations, characterized their functional consequences and investigated the genetic mechanisms leading to FHH3. AP2σ2 mutations were identified in 17 probands, comprising 5 Arg15Cys, 4 Arg15His and 8 Arg15Leu mutations. A genotype–phenotype correlation was observed with the Arg15Leu mutation leading to marked hypercalcaemia. FHH3 probands harboured additional phenotypes such as cognitive dysfunction. All three FHH3-causing AP2σ2 mutations impaired CaSR signal transduction in a dominant-negative manner. Mutational bias was observed at the AP2σ2 Arg15 residue as other predicted missense substitutions (Arg15Gly, Arg15Pro and Arg15Ser), which also caused CaSR loss-of-function, were not detected in FHH probands, and these mutations were found to reduce the numbers of CaSR-expressing cells. FHH3 probands had significantly greater serum calcium (sCa) and magnesium (sMg) concentrations with reduced urinary calcium to creatinine clearance ratios (CCCR) in comparison with FHH1 probands with CaSR mutations, and a calculated index of sCa × sMg/100 × CCCR, which was ≥ 5.0, had a diagnostic sensitivity and specificity of 83 and 86%, respectively, for FHH3. Thus, our studies demonstrate AP2σ2 mutations to result in a more severe FHH phenotype with genotype–phenotype correlations, and a dominant-negative mechanism of action with mutational bias at the Arg15 residue.


International Journal of Pediatric Otorhinolaryngology | 2015

Conservative or radical surgery for pediatric papillary thyroid carcinoma: A systematic review of the literature

Xi Jin; Liam Masterson; Anant Patel; Liz Hook; James Nicholson; S.J. Jefferies; Mark Gaze; Ramez Nassif; Robert Eller; Tony Hulse; Piyush Jani

BACKGROUND Pediatric papillary thyroid carcinoma (PTC) is characterized by an aggressive clinical course. Early diagnosis is a challenge and treatment consists principally of partial or total thyroidectomy±neck dissection and radioactive iodine therapy. Due to the rarity of PTC in children, there is no consensus on optimal surgical treatment. METHODS AND RESULTS A literature search was carried out using PubMed, Embase, Medline, Cochrane and Web of Science. Seven studies (489 patients) investigating the outcome of surgically managed pediatric PTC were identified. No clear advantage in survival or recurrence rate was found for total thyroidectomy compared to other surgical approaches. CONCLUSION Despite the aggressive behavior of PTC, prognosis is good, with low mortality. After removal of disease and prevention of recurrence, reduction of iatrogenic complications are a priority in this age group. Due to the paucity of available evidence, this review cannot recommend conservative or radical surgery for pediatric papillary thyroid carcinoma. To answer this question, we recommend the establishment of a randomized controlled trial with adequately matched baseline variables.


Endocrine Abstracts | 2018

Impact of iodine deficiency on thyroid function in vegan siblings

Agnieszka Brandt; Michal Ajzensztejn; Sophia Sakka; Moira Cheung; Tony Hulse


Endocrine Abstracts | 2018

Prolactinoma in Childhood and Adolescence - outcomes relating to the size of tumour

Ved Bhushan Arya; Ritika R. Kapoor; Tony Hulse; Michal Ajzensztejn; Jennifer Kalitsi; Nicolas Kalogirou; Istvan Bodi; Nick Thomas; Tim Hampton; Simon Aylwin; Charles Buchanan


Endocrine Abstracts | 2018

MEN2B and MTC: the challenge of early diagnosis

Sonia Gomes; Louise Izatt; Tony Hulse


Endocrine Abstracts | 2018

Network-wide audit of 'hypo supplies' availability in children and adolescents with type 1 diabetes mellitus - interim results

Shankar Kanumakala; Michal Ajzensztejn; Christina Jones; Sereesha Veleshala; Usha Parkash; Tony Hulse


45th Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2017

Role of Degludec in improving diabetes outcomes in young people - An observational study from Young Diabetes Connections (YDC) Network, London

Aparna K.R. Nambisan; Samantha Fredriksen; Amy Rowland; Hannah Morrow; Marie Castro-Gonzalez; Michal Ajzensztejn; Tony Hulse; Joanna Lawrence; Ahmed Shamekh; Martha Ford-Adams; Simon Chapman


45th Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2017

Differences in HbA1c among different ethnicities

Alessandra Cocca; Edward Holloway; Charles Buchanan; Tony Hulse


45th Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2017

SOX3 gene duplication (OMIM 313430) associated with midline CNS malformations, hypopituitarism and neurodevelopmental abnormalities: 3 unrelated cases

Aparna K.R. Nambisan; Ritika R. Kapoor; Michal Ajzensztejn; Tony Hulse; Charles Buchanan

Collaboration


Dive into the Tony Hulse's collaboration.

Top Co-Authors

Avatar

Michal Ajzensztejn

Guy's and St Thomas' NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John McKnight

Western General Hospital

View shared research outputs
Top Co-Authors

Avatar

Ken Darzy

Queen Elizabeth II Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge